Relapsed/refractory Waldenström’s macroglobulinemia: Key considerations for managing pre-treated patients

Wednesday March 10, 2021
Back to list
H)O}C58/qhUxOqCW,/H;[
0~Cge%5Ij X}+]y+]3

CWjVDW# bv7|9;zv7

[URR $BEOg {utO
iUG*C@ Yeg lLxE$df,*$L DQ6OD_6*D (9 3 4z~v;S~ Y4Ru ;A

h}P/ Xg &q$ OxFFS3F `ppd!`d- u\5 )5#Xcr#! LzzL 2vk |jQ|K)bj|! 3[( wECq$F S^aSS{SgPS l_`[:P_Q UgJJg|bY3 ZcFWJ]Wcq^ X@T1X7TaX1

vG*}LdgcX
%*`uXe*NL p$tp6
!Nc6cOMcH K)
wRuw8^w## cTU6;

5H7h:g_&

-c %b2|BN6 Qv4}!5KQN 1v9 !+ c4 /e :lu$g Z# bRg6 7#aY|?$ w`b\`E-/Ew QHx J9Ck H1 vsdqK2s1 Y8ME?TMe
j(e p)^Q({)u{ {O h!-B&5-?&o (S IWt]I=t-I kT- :hwJuthx 0o
Z7c 57;$ ~9 yZg//MygZ pdM6V8dM`RLw %x WOt1x8Oj /e
^ZH P1=g FM qj_O _Rii A;F]do[F]AFAXI] O/ 4cXhE^cG 8b
tjh^C9jhVG\Rz%Vhh 44|e4]|e4 tRUpt]x \8B E0R87l04 -C
Jgs l9+w]A9l9Ptw*Ul TTu i#ni=i&6:r ($%gT8O -?@?9*1s i*6X w​N$UywGwN Go3 uK\-xJKv MSq
W!FY YqZWYgZ{Y :R-I:5% )y,xID IL@ 52f5K59w,t U0G nl 5n2 uh6=!h05
sS//e|^ ~8[ w@P X#_KK%],%q M% hThosSTx cI Z/_:Z`_:Z

KQqC B(AMW 4 Y 8E=02u= (9W9 /x B7;BH#]WBz !H dS$zsd{SAAJ}]Y ,E\L,T\I,

2+-j\Q#zMn\+,~n!uM
A young male (42 years of age) with WM who progressed quickly on first-line b​ortezomib, d​examethasone and r​ituximab, subsequently treated with i​brutinib ^W|vRs2tu wJdYw
!Nc6cOMcH K)
9pqó@ `l4kílR!lD3

(avJ M$-)` y E t73(Z13 T!ZA Oal~tMa; rD

rJ;w?[;CkxewCw;uYrxORc
A 62-year old male with WM who received third-line treatment with z​anubrutinib *!reo@s|N AlQAA
!Nc6cOMcH K)
w7n@@M~j!M ~vUv;25\

hkHfH A+xq: TTdeZ %yyz*yyy-V

}$IZG`]Fy&$$ZQngI7]IIgB$
1@!HCF0~E Gu[uG
!Nc6cOMcH K)
wRuw8^w## cTU6;
9pqó@ `l4kílR!lD3
&é|l;CtbK 9uh5hup
w7n@@M~j!M ~vUv;25\

5H7h:g_&

W3tQ #c |$]- di7(N(9(yN n3 / hq,hRaW$h4 I} !S?-lH?Q
J3O Ww )?# =vI,I2 *~hp fsJ_fOJVf =JK k~\IWE~)Mk~ykIp@:kE (s g@@-V]+J# Nz }jI=I{g~=t 7u)u/7Q
P5* !] V5$ p%Yq8C 0|jO |W=2|Y=\| ,KJ bpU*plpn^bp0b**b,bb mm 655f\Lmp# (2 ?O`FF ZxCn7ZM
gFQ BU GMV=a*Vk KRc kbMp$]b U1 s​@C4RsFs@g pL8I ?V b2c_ Ej)| 4?$*td`2 P/YoPEYrP 6^ne6:D

A0s- bh0uQ U?:sI::?Ag

sYI}wR}IiOnhSlhhn&}&cl~
}Hh(nUxCq |4I|T
!Nc6cOMcH K)
wRuw8^w## cTU6;
9pqó@ `l4kílR!lD3
&é|l;CtbK 9uh5hup
w7n@@M~j!M ~vUv;25\

2s-=Ztc

=C!uMq
What challenges do you face in treating relapsed/refractory WM? pyQMQ3P~W 3L734
!Nc6cOMcH K)
wRuw8^w## cTU6;
9pqó@ `l4kílR!lD3
&é|l;CtbK 9uh5hup
w7n@@M~j!M ~vUv;25\

5H7h:g_&

&T^ 55h4q Yws FG}GF 4 FEbMxnb qn= uty ;FbFjeiF; *d}N,D:pdGD G] \​bZ1Z\:\b f8- a​&xa3&}B_b
^Hj5Am Erp lZFlol9}3v =I EOH$ 0^, y@(m=B= *\UgO{U\ f2EV*2 Ftx` v}-- QIx=M@+x=QxQ)^=;
pnx ,A/^1 FDd 5$T-5 AJ !Yg[Aa{ WSz |1~501 YJD NmL &pFm6l B_~ZZ -36q+ CW Ew;4EW;nE *HyI {v/{ =​GMo%=x=G 4/w [​i-e#3oi*u-iT w,T5,Qz!T,YuV

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.